Share on StockTwits

Shares of InterMune (NASDAQ:ITMN) have been given a consensus rating of “Buy” by the sixteen ratings firms that are presently covering the company, AnalystRatingsNetwork reports. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $40.00.

In other InterMune news, CEO Daniel G. Welch unloaded 3,914 shares of InterMune stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $39.19, for a total value of $153,389.66. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

InterMune (NASDAQ:ITMN) traded up 4.69% on Thursday, hitting $44.01. 646,817 shares of the company’s stock traded hands. InterMune has a 52 week low of $9.32 and a 52 week high of $42.68. The stock’s 50-day moving average is $36.54 and its 200-day moving average is $25.31. The company’s market cap is $4.352 billion.

InterMune (NASDAQ:ITMN) last announced its earnings results on Thursday, May 1st. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the previous year, the company posted ($0.64) earnings per share. The company’s revenue for the quarter was up 188.6% on a year-over-year basis. On average, analysts predict that InterMune will post $-2.32 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on ITMN shares. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of InterMune in a research note on Tuesday. They now have a $51.00 price target on the stock, up previously from $45.00. Separately, analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Finally, analysts at ING Group upgraded shares of InterMune from a “market perform” rating to a “buy” rating in a research note on Monday, May 19th. They now have a $41.00 price target on the stock.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.